Compositions and methods for treatment of neoplastic disease
View Patent ↗Herein we provide cDNA extracted from tumor cells, normal cells or treatment resistant tumor cells that have been transduced with virus capable of altering self and/or tumor associated antigens (VASTA) fused recombinantly to nucleic acids encoding wild type superantigens, superantigens, superantigen homologues and superantigen-tumor specific targeting molecules and further linked to a costimulatory molecule. The extracted cDNA is linked to a VASTA and delivered to tumor bearing hosts parenterally wherein they induce a tumoricidal response. These agents are also incorporated into a tumor tropic cell carrier for protected delivery to tumor.
1. A method of treating a subject with a tumor comprising the steps of:
(i) transducing a normal cell or a tumor cell of the same histologic type as said normal cell or a treatment resistant tumor cell of the same histologic type as said tumor cell with a virus or its genomic DNA, wherein said virus or said genomic DNA is operatively linked to nucleic acids encoding a superantigen, and
(ii) extracting the DNA individually from each transduced tumor cell or normal cell or treatment resistant tumor cell encoding the superantigen and at least one self or tumor protein that has been altered in expression level or structure by the said virus or said superantigen, and
(iii) incorporating less than 4000 base pairs of said individually extracted DNA into said virus or its genomic DNA, and
(iv) administering to said subject parenterally by infusion or injection a tumoricidally effective amount of at least one of said viruses or said genomic DNA from at least one of said viruses, wherein said virus incorporates said extracted DNA and said genomic DNA incorporates said extracted DNA.
2. The method according to claim 1 wherein the nucleic acids encoding the superantigen consists of:
(i) a native staphylococcal enterotoxin protein which native protein:
(a) has the biological activity of stimulating T cell mitogenesis via a T cell receptor vβ region; or
(ii) a biologically active homologue or fragment of a native staphylococcal enterotoxin which homologue or fragment:
(a) has the biological activity of stimulating T cell mitogenesis via a T cell receptor vβ region and
(b) has sequence homology characterized as a z value exceeding 13 when the sequence of the homologue or said fragment is compared to the sequence of a native staphylococcal enterotoxin or a native streptococcal pyrogenic exotoxin, determined by FASTA analysis using gap penalties of −12 and −2, Blosum 50 matrix and Swiss-PROT or PIR database.
3. The method according to claim 1 wherein said virus or its genomic DNA is vesicular stomatitis virus.
4. The method according to claim 1 wherein the said transduced treatment resistant tumor cell is resistant to previous chemotherapy.
5. The method of claim 1 wherein said transduced normal cell, tumor cell or treatment resistant tumor cell is autologous to the subject being treated.
6. The method of claim 1 , wherein at least two of said viruses or said genomic DNA from the two of said viruses are administered to the patient.
7. The method of claim 1 , wherein three of said viruses or said genomic DNA from the three of said viruses are administered to the patient.